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ABSTRACT
The underlying mechanisms responsible for the development of castration-
resistant prostate cancer (CRPC) in patients who have undergone androgen 
deprivation therapy are not fully understood. This is the first study to address whether 
β2-adrenergic receptor (ADRB2)- mediated signaling may affect CRPC progression 
in vivo. By immunohistochemical analyses, we observed that low levels of ADRB2 is 
associated with a more rapid development of CRPC in a Norwegian patient cohort. 
To elucidate mechanisms by which ADRB2 may affect CRPC development, we stably 
transfected LNCaP cells with shRNAs to mimic low and high expression of ADRB2. 
Two UDP-glucuronosyltransferases, UGT2B15 and UGT2B17, involved in phase II 
metabolism of androgens, were strongly downregulated in two LNCaP shADRB2 
cell lines. The low-ADRB2 LNCaP cell lines displayed lowered glucuronidation 
activities towards androgens than high-ADRB2 cells. Furthermore, increased levels 
of testosterone and enhanced androgen responsiveness were observed in LNCaP 
cells expressing low level of ADRB2. Interestingly, these cells grew faster than high-
ADRB2 LNCaP cells, and sustained their low glucuronidation activity in castrated NOD/
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INTRODUCTION
Androgen deprivation therapy (ADT) is the first 
line of treatment for patients with advanced or metastatic 
prostate cancer [1]. ADT is initially effective in controlling 
tumor growth and symptoms, but most tumors eventually 
develop resistance to ADT and become castration 
resistant prostate cancers (CRPC). Over the last years, 
it has become evident that the androgen signaling axis 
plays a pivotal role in the development of CRPC [2]. The 
multiple molecular mechanisms by which the androgen 
receptor (AR) contributes to disease progression despite 
castration levels of androgens in prostate cancer have 
been thoroughly reviewed [3-6]. Several new targets 
in the AR activation pathway have emerged in recent 
years [7, 8]. The steroidogenic pathway has received 
increasing attention, as drugs targeting this pathway, such 
as abiraterone (an inhibitor of cytochrome P450, family 
17, subfamily A, polypeptide 1 (CYP17)) improve the life 
expectancy of patients with CRPC, despite the assumed 
androgen-independence of these cancer cases [8]. No 
curative options for CRPC are, however, available today. 
Increased knowledge of the mechanisms by which the 
cancer cells progress to CRPC is hence needed. Recently, 
targeting the androgen extrahepatic phase-II metabolic 
pathways has arisen as a potential tool to help maintain 
androgen-deprived conditions during ADT [9]. The UDP-
glucuronosyltransferases 2B15 (UGT2B15) and 2B17 
(UGT2B17) are of special interest, as they are expressed 
in prostate tissue and cell lines, and they exhibit specificity 
for androgen metabolites [10].
The β2-adrenergic receptor (ADRB2) and its 
downstream effectors cyclic AMP (cAMP) and cAMP-
dependent protein kinase A (PKA) have been implicated 
in prostate cancer progression and AR signaling [11]. In 
particular, sympathetic stimulation of ADRB2 has been 
shown to potentially sensitize AR in cell lines under 
androgen depleted conditions [12], suggesting that 
ADRB2 might play a role in the development of CRPC. 
Furthermore, a number of target genes are common for 
the androgen and the PKA signaling cascades [13], and in 
steroidogenic cells both cAMP and PKA have been shown 
to regulate transcription of steroidogenic genes such as 
CYP17 and STAR [14-16], as well as to modulate their 
activity at the protein level [17].
While most pre-clinical evidence points towards a 
tumor promoting role of β-adrenergic signaling [18, 19], a 
previous study by Yu et al. reported an inverse correlation 
between ADRB2 expression levels and prostate cancer 
progression [20]. Low levels of ADRB2 in prostate cancer 
tissue were found to correlate with biochemical recurrence 
measured as increasing prostate-specific antigen (PSA) 
levels, or metastatic disease after radical prostatectomy. 
Conversely, our group has recently reported an association 
between the use of β-blockers (ADRB antagonists) and 
improved prostate cancer specific survival both for 
patients who have undergone ADT [21] and for patients 
with high risk or metastatic disease [22].
Our knowledge about the potential role of the 
ADRB2 in prostate cancer and CRPC development is still 
limited. Therefore, in this study, we have addressed this 
topic by performing immunohistochemical analyses and 
investigated the potential role of ADRB2 in development 
of CRPC in ADRB2 knockdown cell lines. 
RESULTS
Low ADRB2 expression level in tumor tissue is 
associated with poor prognosis after androgen 
deprivation therapy
Tissue from 45 prostate cancer patients who had 
received hormonal therapy and had been treated with 
transurethral resection of the prostate (TUR-P) at Oslo 
University Hospital, Aker (the Oslo ADT cohort) were 
included in a tissue micro-array study. Five patients 
were excluded due to lack of cancerous tissue following 
staining with anti-ADRB2 antibody. The mean follow-up 
from initiation of ADT for the 40 patients included in the 
survival analyses was 71 months. For prostate cancer- 
specific mortality the mean follow-up was 70 months, 
as we lacked information on the cause of death for four 
patients. Patient and tumor characteristics at time of 
diagnosis are shown in Supplementary Table 2. Examples 
of negative and strong ADRB2 staining of two specimens 
with Gleason score 9 are shown in Figure 1a and 1b. 
Kaplan-Meier plots showing time to CRPC development 
and prostate cancer- specific mortality in patients stratified 
according to staining intensity above and below mean are 
shown in Figure 1c and 1d. Competing risk regression 
modelling showed that increasing staining intensity was 
associated with increased time to CRPC development, 
with an adjusted SHR of 0.67 (95% CI 0.46-0.97, p-value 
0.035; adjusted for age at initiation of ADT and Gleason 
score) (Table 1). For prostate cancer- specific mortality, 
the association was not statistically significant (adjusted 
SCID mice. ADRB2 immunohistochemical staining intensity correlated with UGT2B15 
staining intensity in independent TMA studies and with UGT2B17 in one TMA study. 
Similar to ADRB2, we show that low levels of UGT2B15 are associated with a more 
rapid CRPC progression. We propose a novel mechanism by which ADRB2 may affect 
the development of CRPC through downregulation of UGT2B15 and UGT2B17.
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SHR 0.70, 95% CI 0.42-1.15, p-value 0.16). ADRB2 
levels had no impact on all-cause mortality (adjusted HR 
0.91, 95% CI 0.61-1.37, p-value 0.66). 
A correlation analysis indicated no association 
between ADRB2 expression level and duration of ADT 
before TUR-P surgery (correlation coefficient -0.21, 
p-value 0.23).
LNCaP shADRB2-tumors grow more rapidly in 
castrated mice
Aiming to reveal potential mechanisms explaining 
the observed correlation between ADRB2 expression 
and time to CRPC development, we stably transfected 
LNCaP cells with shRNA plasmids targeting ADRB2 
mRNA, yielding two knockdown cell lines (shADRB2-1 
Table 1: Uni- and multivariable HRs/SHRs for ADRB2 staining intensity and CRCP development and prostate cancer- 
specific and all-cause mortality.
Cumulative 
incidence
Increasing ADRB2 staining intensity
Crude estimate
SHR/HR (95 % CI) p-value
Multivariable analysisa
SHR/HR (95% CI) p-value
Development of CRPC b 27/40 0.77 (0.53-1.13) 0.18 0.67 (0.46-0.97) 0.035
Prostate cancer- specific mortalityb 21/35 0.71 (0.47-1.08) 0.11 0.70 (0.42-1.15) 0.16
Overall mortality 36/40 0.74 (0.53-1.04) 0.082 0.91 (0.61-1.37) 0.66
a Adjusted for age at initiation of androgen deprivation therapy and highest Gleason score from HE-slides of the TMA 
b Analyzed by competing risk regression
Figure 1: ADRB2 level is positively correlated with time to CRPC development. Immunohistochemical analysis of ADRB2 
expression in a TMA of transurethral resections of the prostate (TUR-P). Examples of tissue cores of Gleason score 9 tumors showing 
negative a. or strong staining b. intensity (original magnification 20x). Kaplan-Meier plots showing time to CRPC development c., and time 
to prostate cancer (PCa)- specific death d. following TUR-P in patients stratified according to strong and weak staining intensity of ADRB2. 
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and 2), as well as a non-targeting shRNA plasmid 
(shCtrl). Real-Time RT-PCR analyses on mRNA isolated 
from shADRB2 and shCtrl cells revealed a 50% and 
95% reduction of ADRB2 mRNA in shADRB2-1 and 
shADRB2-2, respectively, compared to shCtrl (Figure 
2a). Radiolabeled ligand-binding assay measuring 
125I-cyanopindolol (CYP)-binding to membrane-bound 
ADRBs confirmed the knockdown, with 50% and 85% 
lowered ADRB binding activity in shADRB2-1 and 
shADRB2-2 cells, respectively (Figure 2b). The receptor 
acts primarily through stimulating adenylyl cyclase (AC) 
activity, resulting in increased cAMP levels. The basal 
(non-stimulated) rate of conversion of [α-32P]ATP to [32P]
cAMP was significantly lowered in both shADRB2-1 and 
2 as shown in Figure 2c. Furthermore, stimulation with 
the non-selective ADRB-agonist isoproterenol showed a 
larger absolute and relative increase in adenylyl cyclase 
activity in shCtrl compared to both shADRB2 cell lines, 
indicating a functional effect of reduced ADRB2 levels. 
LNCaP shADRB2-2 and shCtrl cells were injected 
into NOD-SCID mice. The mice were castrated when 
the tumor diameter reached 10-12 mm and the tumor 
growth was followed in castrated mice for up to 42 days. 
After a brief lag period, the shADRB2-2 tumors grew 
more rapidly after castration, as shown in Figure 3a. 
Although the ten mice in the shADRB2-2 group had non-
significantly smaller tumors than the eleven mice in the 
shCtrl group at time of castration, the shADRB2-2 tumors 
were larger 28 days after castration. The change in tumor 
volume from day 0 to day 42 was 3.5 fold higher in the 
shADRB2-2 compared to the shCtrl group (Figure 3b).
Figure 2: ADRB2 level, receptor binding, and downstream signaling activity in LNCaP shADRB2 cell lines. a. ADRB2 
mRNA levels were semi-quantitatively measured in RNA isolated from two LNCaP shADRB2 (shADRB2-1 and shADRB2-2) cell lines 
and a non-targeting shRNA LNCaP cell line (shCtrl) using Real-Time RT-PCR. Mean, ΔΔCt calculated values relative to shCtrl cells 
are shown. b. β-adrenergic receptor level was quantified by determination of 125I-CYP specific binding to membrane protein fractions 
isolated from two LNCaP shADRB2 cell lines and shCtrl cells. Bars represent β-adrenergic receptor level reported as fmol/mg protein 
in the membrane fraction. c. Adenylyl cyclase activities in membranes isolated from LNCaP shADRB2 and shCtrl cells treated with 
vehicle or 10 µM isoproterenol were measured. The bars represent mean rate of formation of cAMP normalized to total protein in the 
membrane fractions (fmol/mg protein/min). All experiments were performed in biological triplicates (n = 3), mean ± standard deviation 
(SD). Statistical significance is indicated by asterisks (*: p < 0.05; **: p < 0.01; ***: p < 0.001). 
Figure 3: LNCaP shADRB2 xenograft tumors grow more rapidly than shCtrl tumors in castrated mice. LNCaP 
shADRB2-2 and shCtrl cells were implanted subcutaneously into nude NOD-SCID mice. Once tumors reached 500 mm3 in size, mice were 
surgically castrated and taken off testosterone supplementation. Tumor volumes were measured weekly for 6 weeks. The graph a. shows 
mean (n = 10 for shADRB2-2 and 11 for shCtrl) tumor volumes (mm3) ± SEM. b. Box-and-whisker plot showing the percentage change in 
tumor volume 42 days after castration in NOD-SCID mice injected with LNCaP shADRB2-2 and shCtrl cells. Statistical significance was 
measured by Fischer exact test, and is indicated by asterisks (*: p < 0.05). 
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Table 2: Spearman's rank correlations between ADRB2 and UGT2B15 and UGT2B17
ADRB2 versus UGT2B15 ADRB2 versus UGT2B17
TMA study Cohort No. of pairs Correlation (95% CI) p-value No. of pairs
Correlation (95% CI) 
p-value




All cancer cases 583 0.40 (0.33-0.47) <0.0001 602 0.35 (0.27-0.42) <0.0001
Recurrent PCa 209 0.50 (0.38-0.59) <0.0001 214 0.33 (0.20-0.45) <0.0001
CRPC 58 0.64 (0.45-0.78) <0.0001 58 0.33 (0.074-0.55) 0.011
Figure 4: UGT2B15 and UGT2B17 mRNA, protein and effects on androgen glucuronide formation. a. UGT2B15 and 
UGT2B17 mRNA levels were measured in RNA isolated from LNCaP shADRB2 (shADRB2-1 and shADRB2-2) and shCtrl cells using 
Real-Time RT-PCR. Bars represent mean, ΔΔCt calculated values relative to shCtrl cells (n = 3) ± SD. b. UGT2B15 and UGT2B17 protein 
levels were visualized in cell homogenates by immunoblotting using anti-UGT2B15 and anti-UGT2B17 antibodies. Anti-actin antibodies 
were simultaneously used on the same homogenates to ensure similar loading on the lanes. c.-f. Cell homogenates from two LNCaP 
shADRB2 cell lines (shADRB2-1 and shADRB2-2) and shCtrl LNCaP cells (shCtrl) were mixed with uridine diphosphate glucuronic 
acid (UDPGA) and either dihydrotestosterone (DHT), 3α-androstanediol (3α-Diol) or androsterone (AND), for one hour, and levels of 
glucuronidated (G) androgens (c: DHT-G; d: 3α-Diol-17G; e: 3α-Diol-3G; f: AND-G)  were measured by LC-MS/MS. The results are 
shown as mean formed glucuronide related to total protein in the homogenates (pmol/min/mg protein) from duplicated reactions on three 
biological replications ± SD. Statistical significance is indicated by asterisks (*: p < 0.05; **: p < 0.01; ***: p < 0.001).
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Knockdown of ADRB2 in LNCaP cells is 
associated with reduced androgen glucuronidation 
activity
We performed gene expression profiling of the 
LNCaP shADRB2 and shCtrl cells to aid in elucidating 
potential mechanisms explaining the association between 
ADRB2 and CRPC development, as well as the increased 
growth of the shADRB2 xenograft tumors. From this 
microarray analysis we observed differential expression 
of UDP-glucuronosyltransferase 2B15 and 2B17 in 
shADRB2 cells compared to the shCtrl cells (data not 
shown). To corroborate the microarray data, we performed 
Real-Time RT-PCR which showed that UGT2B15 was 
down-regulated 5-fold and 6-fold, and UGT2B17 down-
regulated 10-fold and 20-fold, in shADRB2-1 and 2 
respectively, relative to shCtrl (Figure 4a). The UGT2B15 
and UGT2B17 protein levels were visualized by 
immunoblotting analysis. Whereas both proteins showed 
strong bands in shCtrl cells, UGT2B15 and UGT2B17 
were virtually un-detectable in both shADRB2 cell lines 
(Figure 4b).
Furthermore, lowered UGT2B15 and 
UGT2B17 expression was accompanied by reduced 
androgen glucuronide formation (Figure 4c-4f). 
Dihydrotestosterone-glucuronide (DHT-G), two 
androstanediol glucuronides (3α-Diol-17G, 3α-Diol-3G) 
and androsterone glucuronide (AND-G) formation was 
strongly reduced in the shADRB2 cell lines compared to 
shCtrl cells, with a steady 85% lowering of glucuronide 
formation in shADRB2-1 cells, and a 95% fold lowering 
in shADRB2-2 cells. Glucuronidation activity in positive 
(human liver homogenates) and negative (HEK293 cell 
homogenates) controls is shown in Supplementary Figure 
1.
These findings led us to investigate whether 
castration of mice injected with LNCaP shCtrl or 
shADRB2-2 cells had an effect on the expression 
and activity of UGT2B15 and UGT2B17 in vivo. 
Immunohistochemical staining of tumor tissue from the 
xenograft study using anti-UGT2B15 and anti-UGT2B17 
antibodies showed that the phenotypic differences between 
shCtrl and shADRB2-2 cells were maintained also after 
castration (Figure 5a). UGT2B15 and UGT2B17 staining 
intensities were statistically significantly higher in 
shCtrl tumors than shADRB2-2 tumors (p = 0.006 and 
p = 0.0004 for UGT2B15 and UGT2B17, respectively). 
UGT2B17 negatively correlated to average daily growth 
of the tumors (correlation coefficient -0,518, p = 0.016), 
whereas UGT2B15 did not (correlation coefficient -0.188, 
p = 0.41). Furthermore, the glucuronidation activity in 
tumor extracts was on average 85% lower in shADRB2 
xenograft mice compared to shCtrl mice (Figure 5b-5e).
Knockdown of ADRB2 improves androgen 
responsiveness in vitro
After confirming that lowered ADRB2 expression 
lead to a change in glucuronidation activity, we were 
interested in finding out whether this could provoke a 
Table 3: A) Uni- and multivariable HRs/SHRs for UGT2B15 staining intensity and CRCP development and prostate 
cancer- specific and all-cause mortality. B) Uni- and multivariable HRs/SHRs for UGT2B17 staining intensity and CRCP 
development and prostate cancer- specific and all-cause mortality.
A) Cumulative incidence
Increasing UGT2B15 staining intensity
Crude estimate
SHR/HR (95 % CI) p-value
Multivariable analysisa
SHR/HR (95% CI) p-value
Development of CRPC b 22/33 0.63 (0.32-1.25) 0.19 0.39 (0.16-0.97) 0.043
Prostate cancer- specific 
mortalityb 15/28 0.63 (0.30-1.32) 0.22 0.38 (0.09-1.59) 0.19
Overall mortality 29/33 0.67 (0.37-1.22) 0.19 0.90 (0.42-1.95) 0.80
B) Cumulative incidence
Increasing UGT2B17 staining intensity
Crude estimate
SHR/HR (95 % CI) p-value
Multivariable analysisa
SHR/HR (95% CI) p-value
Development of CRPC b 23/34 1.06 (0.55-2.05) 0.87 0.87 (0.43-1.73) 0.69
Prostate cancer- specific 
mortalityb 16/29 0.89 (0.46-1.71) 0.72 0.69 (0.41-1.16) 0.16
Overall mortality 30/34 0.93 (0.52-1.67) 0.80 1.17 (0.60-2.30) 0.65
a Adjusted for age at initiation of androgen deprivation therapy and highest Gleason score from HE-slides of the TMA 
b Analyzed by competing risk regression
Oncotarget1884www.impactjournals.com/oncotarget
change in the AR activity in the cells. DHT-stimulated 
LNCaP shADRB2 and shCtrl cells transiently transfected 
with the probasin-based promoter and luciferase reporter 
construct 285-Pb-pEZX-PG04 revealed that shADRB2 
cells had a higher relative androgen responsiveness than 
shCtrl cells (7-fold and 4-fold in shADRB2-1 and 2, 
respectively) (Figure 6a). Similar results were obtained 
when the cells were pre-incubated for 96 hours in 
hormone-deprived medium prior to stimulation (data not 
shown). To test if the effect was caused by reduced level 
of ADRB2, we rescued ADRB2 expression in shADRB2-1 
and 2 using pCDNA3.1-ADRB2, constitutively expressing 
the ADRB2 gene. The relative luciferase activity was 
decreased by 80% and 50%, yielding the knockdown cells 
Figure 5: LNCaP shADRB2 castrated mouse tumor characteristics and glucuronidation activity. a. Excised xenograft 
tumors were formalin-fixed and paraffin-embedded, and sections were stained with anti-UGT2B15 (1:500) and anti-UGT2B17 (1:500) 
antibodies. Frequencies of staining intensities (weak, intermediate and strong) from tumors derived from mice injected with shCtrl (n = 
11) and shADRB2-2 (n = 10) LNCaP cells are shown. b.-e. Fresh frozen tumor tissue from the same mice were homogenized and added 
UDPGA and either dihydrotestosterone (DHT), 3α-androstanediol (3α-Diol) or androsterone (AND) in a glucuronidation assay. Formation 
of steroid glucuronides (c: DHT-G; d: 3α-Diol-17G; e: 3α-Diol-3G; f: AND-G)  was measured by LC-MS/MS. The results are shown as 
a box-and-whisker plot showing formed glucuronide related to total protein in the tissue homogenates (pmol/min/mg tissue protein) from 
triplicate reactions on the same homogenates. Statistical significance is indicated by asterisks (**: p < 0.01; ***: p < 0.001).
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more similar to shCtrl cells (Figure 6b). Furthermore, 
we wanted to test if the effect observed with a probasin-
based promoter (285-Pb-pEZX-PG04) could be replicated 
with a different androgen responsive reporter plasmid 
containing 7 kb of the 5’ upstream region of the PSA 
promoter (pGL3/PSA). We transfected shADRB2 and 
shCtrl cells with pGL3/PSA and measured relative 
androgen responsiveness after stimulation with 10 nM 
DHT or vehicle for 48 hours. As with 285-Pb-pEZX-
PG04, the androgen response of pGL3/PSA was higher 
when transfected into shADRB2 cells than shCtrl cells 
(2.5- and 1.8-fold higher in shADRB2-1 and shADRB2-2, 
respectively) (Figure 6c).
Next, we were interested in seeing whether the 
androgen responsiveness could be modulated by inhibiting 
UGT2B15 and UGT2B17 activity. We treated LNCaP 
shCtrl cells with the UGT2B substrate diclofenac sodium 
(DFS), which competitively inhibits UGT2B-action 
towards androgens. Stimulation with 50 µM diclofenac 
sodium induced a statistically significant 1.8-fold rise in 
normalized 285-Pb-pEZX-PG04-driven luciferase activity 
(Figure 6d).
Figure 6: Increased androgen responsiveness in LNCaP shADRB2 cell lines. a. LNCaP shADRB2-1, shADRB2-2 and shCtrl 
cells were transfected with the androgen responsive element-containing luciferase reporter construct 285-Pb-pEZX-PG04. The following 
day, cells were incubated in hormone-deprived medium containing 2% CSS supplemented with either 10 nM DHT or vehicle and further 
incubated for 48 hours. The androgen responsiveness of 285-Pb-pEZX-PG04 in LNCaP shADRB2-1, shADRB2-2, and shCtrl cells are 
shown relative to vehicle treated (n = 3) ± SD. . b. LNCaP shADRB2-1 and shADRB2-2 were transfected with the reporter construct 
285-Pb-pEZX-PG04 and either an ADRB2 expression vector (pCDNA3.1-ADRB2) or a control expression vector (pEGFP-C3). Mean 
androgen responsiveness relative to vehicle treated cells is shown (n = 3) ± SD.. c. Cells were transfected with a reporter plasmid including 
the 5’-regulatory region of PSA (pGL3/PSA), and the cells were stimulated as described in (a). Androgen responsiveness is given as the 
relative luciferase activities from DHT-stimulated cells normalized to vehicle-treated cells from three independent experiments (n = 3) 
mean ± SD. d. shCtrl cells were transfected with 285-Pb-pEZX -PG04 and were either treated with 50 µM diclofenac or with vehicle and 
then half of the cells were stimulated with 10 nM DHT the following day and all cells were harvested after 72 hours. Mean DHT responses 
from three independent experiments are shown relative to un-stimulated shCtrl cells (given value 1.0) ± SD treated with either diclofenac 
or vehicle ± SD. Statistical significance is indicated by asterisks (*: p < 0.05; **: p < 0.01; ***: p < 0.001). 
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The androgen responsiveness was non-significantly 
higher in the shADRB2-1 cell line than in the shADRB2-2 
cell line (Figure 6a). This might be due to the fact that the 
androgen receptor is slightly induced in the shADRB2-1 
cell line (measured by western immunoblotting of protein 
extracts; Supplementary Figure 2). The androgen receptor 
was not up-regulated in shADRB2-2 cells compared to 
shCtrl.
Prostate-specific antigen responsiveness is 
increased in ADRB2 knockdown LNCaP cells
We hypothesized that increased reporter-driven 
androgen responsiveness would be mirrored by an 
increase in the PSA response upon androgen stimulation. 
shADRB2 and shCtrl cells were pre-incubated in 
hormone-deprived medium for 96 hours, and then 
stimulated for 48 hours with either 1 nM DHT, 1 nM 
R1881, or vehicle, before harvesting and isolating total 
RNA. The Real-Time RT-PCR reaction revealed that DHT 
induced a significantly more pronounced response on PSA 
mRNA in both shADRB2 cell lines than in shCtrl (Figure 
7a). Stimulation with the non-glucuronidable synthetic 
androgen R1881 resulted in a greater response in all the 
cells compared to DHT, but there were no significant 
differences between shADRB2 and shCtrl cells (Figure 
7b). To substantiate these findings, we performed a similar 
experiment where we measured secreted PSA in medium 
from androgen-stimulated cells. Figure 7c shows the 
androgen responsiveness from cells stimulated with DHT, 
and Figure 7d shows the relative responses acquired with 
R1881. As with PSA mRNA, only stimulation with DHT 
yielded a significant difference in increased PSA-response 
between shADRB2 cell lines and the shCtrl cell line.
Figure 7: Prostate-specific antigen responsiveness is higher in shADRB2 than in shCtrl cells. a., b. LNCaP shADRB2 and 
shCtrl cells were starved in 2% CSS for 96 hours prior to stimulation with 1 nM DHT or 1 nM R1881 for 48 hours. RNA was harvested and 
analyzed for PSA/KLK3 mRNA expression by Real-Time RT-PCR. Gene expression upon stimulation with a. DHT and b. R1881 relative 
to non-stimulated cells (vehicle) was calculated by the ∆∆Ct- method. Bars represent log2-transformed androgen responses (n = 3) ± SEM. 
c., d. Secreted total PSA (TPSA) was measured in medium samples from cells stimulated with c. DHT and d. R1881 by time-resolved 
fluorescence, and was related to non-stimulated cells (vehicle). Bars represent androgen responses (n = 4) mean ± SD. NS: non-significant 
difference from shCtrl.
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Glucuronidation activity affects androgen levels 
in LNCaP ADRB2 knockdown cells
A plausible effect of lowered glucuronidation 
activity is shifting of the substrate/glucuronide 
homeostasis and subsequent accumulation of 
glucuronidable androgens, which could help explain 
the observed increase in androgen responsiveness in 
shADRB2 cells. We therefore measured intracellular 
testosterone levels in shCtrl and shADRB2 cells cultured 
in FCS medium for 48 hours (Figure 8a). An 11-fold 
and 5.5-fold higher testosterone level was found in 
shADRB2-1 and shADRB2-2, respectively, compared to 
shCtrl. The basal reporter activity driven by the androgen 
responsive probasin promoter (pPB(-285/132)-LUC) 
was higher in shADRB2 cell lines compared shCtrl 
cells (Figure 8b) supporting that the testosterone level is 
increased in shADRB2 cell lines.
Furthermore, to establish a link between 
glucuronidation activity and levels of bioavailable 
androgen, we supplemented shCtrl and shADRB2-2 cells 
with diclofenac sodium and measured the intracellular 
testosterone levels. Diclofenac sodium caused a dose-
dependent induction in testosterone levels, with 17-
fold and 35-fold induction with 50 and 100 µM DFS, 
respectively (Figure 8c). Comparably, diclofenac had 
only a minor effect in shADRB2-2, which has 95% lower 
androgen glucuronidation activity than shCtrl cells. 
UGT2B15 and UGT2B17 are correlated to 
ADRB2 in two patient material data sets
Initially, as we observed a regulation of UGT2B15 
and UGT2B17 levels after ADRB2 knockdown in vitro, 
we wanted to examine if these proteins were correlated 
with ADRB2 expression in the Oslo ADT cohort. Both 
UGT2B15 and UGT2B17 predominantly showed 
cytoplasmic staining of luminal cells (Supplementary 
Figure 3). As can be seen in Table 2, UGT2B15 staining 
was found to be positively correlated with ADRB2 
staining (correlation coefficient 0.39, p-value 0.001). A 
similar trend was found for UGT2B17; however this was 
not statistically significant. 
To verify the results in an independent study, 
immunohistochemical stainings with ADRB2, UGT2B15 
and UGT2B17 were performed on four TMAs, merged 
into a single data set, from the Vancouver Prostate 
Centre Tissue Bank. Of a total of 306 patients, 262 had 
cores positive for cancer. Among these, 96 patients had 
recurrent prostate cancer, 23 had diagnosed CRPC, and the 
remaining 143 were patients who have undergone radical 
prostatectomy. In this cohort, we observed a correlation 
between ADRB2 and UGT2B15 similar to the correlation 
in the Oslo ADT cohort (Table 2). Interestingly, the 
correlation was stronger when only samples from patients 
who have experienced recurrence or who have developed 
castration resistant prostate cancer were included in the 
analysis. In this dataset, the UGT2B17 staining was also 
significantly correlated with ADRB2 staining (Table 2).
Figure 8: Reduced androgen glucuronidation activity affects the level of bioactive androgen in vitro. a. The basal level of 
testosterone was measured in shCtrl, shADRB2-1, and shADRB2-2 LNCaP cells cultured in FCS medium. Steroids were extracted from the 
cells, dried, reconstituted, and run on an LC-MS. Integrated, internal standard (IS)-normalized mean peak areas are shown related to equal 
cell pellets. b. LNCaP shADRB2-1, shADRB2-2 and shCtrl cells were transfected with pPB(-285/132)-LUC. After 72 hours incubation in 
FCS-medium, basal luciferase activity of the pPB(-285/132)-LUC reporter was measured and related to SEAP. The results are shown as 
mean, basal luciferase activities related to shCtrl (given value 1.0) ± SD from three independent experiments. c. LNCaP shADRB2-2 and 
shCtrl cells were treated with 50 or 100 µM diclofenac or vehicle for 48 hours. Integrated, internal standard (IS)-normalized peak areas 
were related to total protein content and is presented as mean relative increase compared to vehicle treated cells (given value 1.0) (nM 
testosterone/mg protein) from three independent experiments ± SD. Statistical significance is indicated by asterisks (*: p < 0.05, **: p < 
0.01, ***: p < 0.001).
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Finally, we performed a competing risk regression 
analysis to see if UGT2B15 and UGT2B17, like 
ADRB2, were associated with development of CRPC in 
the Oslo ADT cohort. 33 and 34 out of the 45 patients 
had successful immunohistochemical staining of tumor 
tissue with UGT2B15 and UGT2B17, respectively. Weak 
UGT2B15 staining intensity was significantly associated 
with a more rapid development of CRPC (SHR 0.39, 
95% CI 0.16-0.97, p-value 0.043), while UGT2B17 was 
not (Table 3). Neither UGT2B15 nor UGT2B17 were 
associated with prostate cancer specific or all-cause 
mortality (Table 3a and 3b, respectively). 
DISCUSSION
We report that prostate cancer patients expressing 
low levels of the β2-adrenergic receptor in the cancer 
tissue more rapidly develop castration-resistant prostate 
cancer. Furthermore, xenograft tumors from prostate 
cancer cells with knockdown of ADRB2 were shown 
to grow more rapidly in castrated mice than xenografts 
tumors from control cells. We have identified a novel 
mechanism by which ADRB2 may indirectly regulate the 
activity of the androgen receptor in prostate cancer cells, 
namely through regulating glucuronidation, a critical 
step in the extrahepatic phase II metabolic elimination 
pathway of androgens. LNCaP cells expressing low 
ADRB2 levels showed reduced UGT2B15 and UGT2B17 
expression and activity compared to cells expressing high 
ADRB2 levels. The low ADRB2 expressing LNCaP cells 
were more responsive to androgen stimuli, displayed 
increased testosterone levels and a higher basal androgen 
receptor activity. Furthermore, supplementation with 
the competitive UGT2B-substrate diclofenac enhanced 
androgen responsiveness in high-ADRB2 expressing 
LNCaP cells, with a simultaneous increase in the intra-
cellular testosterone level. 
Like androgens, adrenergic stimulation contributes 
to prostatic differentiation in vivo [23]. Moreover, ADRB2 
signaling activates androgen responsive promoters in vitro 
and is therefore suggested to play a role in development 
of CRPC [12]. Short-term activation of ADRB2 
stimulates androgen receptor activity [12], while long-
term activation of ADRB2 leads to desensitization of 
ADRB2 [24]. Furthermore, down-regulation of ADRB2 
induces de-differentiation and epithelial to mesenchymal 
transition (EMT) [20], a process associated with CRPC 
development. This is the first study addressing whether 
ADRB2 correlates with CRPC in vivo, and the data are 
consistent with the hypothesis that ADRB2 is associated 
with CRPC.
This study points to a novel mechanism by which 
long-term knockdown of ADRB2 may support CRPC 
development. In xenografts, LNCaP tumors expressing 
low levels of ADRB2 have a shorter lag period and grow 
more rapidly after castration than tumors with normal 
ADRB2-levels, indicating that these cells may be more 
adapted to an androgen-deprived milieu. Being more 
adapted to castration theoretically predicts therapy failure 
or imminent recurring growth, which seems to be the case 
for these shADRB2 tumors. 
The increased testosterone levels and enhanced 
androgen responsiveness observed in ADRB2 knockdown 
cells may relate to the observation that androgen-
glucuronidating activity is down-regulated. Reducing 
glucuronidation could preserve residual and de novo 
biosynthesized androgens and thus rescue androgen 
receptor stimulation, which would give the cells an 
“edge” in an androgen-deprived micro milieu. Thus, 
this may represent an adaption mechanism by which the 
cells maintain a sufficient androgen receptor activity to 
uphold survival. In vivo, this mechanism may complement 
the well-known increase in intra-tumoral androgen 
biosynthesis and androgen receptor expression observed 
in CRPC [25-27]. 
The cAMP signaling pathway is an essential inducer 
of steroidogenesis in steroidogenic cells [14-17]. To what 
extent β-adrenergic signaling regulates steroid synthesis in 
prostate cancer cells is not known, but our study suggests 
that the receptor may be involved in regulating the amount 
of bioactive androgen through modulating glucuronidation 
activity. Testosterone levels were increased both in cells 
expressing low levels of UGT2B15 and UGT2B17, and 
in cells treated with diclofenac, which has previously 
been reported to be a UGT2B15 and UGT2B17 
competitive inhibitor [28-30]. Furthermore, stimulation 
with the synthetic androgen R1881, reported to be non-
glucuronidable [31], gave similar androgen responses in 
the shADRB2 (low UGT2B) and shCtrl (high UGT2B) 
cell lines, indicating that glucuronidation regulates the 
observed differences in androgen responsiveness solitarily. 
In support of this, a study by Chouinard et al., showed 
that knockdown of UGT2B15 and UGT2B17 in LNCaP 
cells lead to a more pronounced modulation of androgen-
regulated genes [32].
Several studies have investigated the expression 
level of UGT2B15 and UGT2B17 in hormone naïve 
and castration resistant prostate cancer [9, 25, 33]. 
Collectively, none of these studies show a significant 
difference in immunohistochemical staining intensity for 
neither UGT2B15 nor UGT2B17 expression between 
androgen-dependent prostate cancer and CRPC. No 
study has yet, however, investigated how UGT2B15- or 
UGT2B17 expression in hormone naïve prostate cancer 
relates to time to development of CRPC. In our analyses, 
UGT2B15 staining intensity was statistically significantly 
correlated with CRPC development, while UGT2B17 was 
not. Both enzymes, however, are positively correlated 
with ADRB2 staining, which itself was associated with 
CRPC development. The positive correlations between the 
two UGT2Bs and ADRB2 in tissue samples support our 
observations of reduced UGT2B15 and UGT2B17 levels 
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after knockdown of ADRB2 in LNCaP cells. Furthermore, 
the finding that differences in glucuronidation activity 
between shCtrl and shADRB2 cells were maintained in 
our mouse model after castration, points to the possibility 
that ADRB2 may influence glucuronidation activity also 
in humans. 
If UGT2B15 and UGT2B17 are important 
determinants of the availability of bioactive androgens 
in the tumor micro milieu in vivo, patients with low 
ADRB2 expression may have a lower response to 
androgen-deprivation therapy through lowered UGT2B15 
and UGT2B17 protein levels. This might explain our 
observation that low ADRB2 levels are associated with a 
poor prognosis.
It should be noted that diclofenac is a non-steroidal 
anti-inflammatory drug, and may thus affect pathways that 
directly or indirectly affect androgen receptor activity, 
i.e. through affecting prostaglandin metabolites that are 
known to inhibit AR [34]. Whether this in turn could affect 
our reported effects on androgen responsiveness was not 
assessed in this study. 
Low level of ADRB2 has previously been shown 
to predict a shorter time to clinical failure after radical 
prostatectomy, as defined by biochemical recurrence 
[20]. It is worth noting, however, that 60-70% of men 
experience recurrence without emergence of clinical 
symptoms, and only around 8% of patients that experience 
biochemical recurrence die from prostate cancer [35]. 
Thus, clinical progression probably serves as a better end 
point in biomarker studies. We used clinical progression as 
an end point, and see that ADRB2 may act as a prognostic 
biomarker for CRPC. Furthermore, alterations in androgen 
glucuronidation activity are presented as one potential 
mechanism by which ADRB2 may regulate development 
of castration resistant prostate cancer. 
MATERIALS AND METHODS
Ethics
The Regional Ethical Committee (s-04153c), the 
Data Protection Official at Oslo University Hospital (41-
2009 AUS) and The Norwegian Data Protection Authority 
(09/00450-2 /bso) has approved this study. Written consent 
was obtained from all surviving patients, and a permission 
to include clinical information on deceased patients was 
obtained from the Regional Committee for Medical and 
Health Research Ethics (2009/1028). 
Patient material and TMA construction
For the Oslo ADT TMA, 61 patients treated with 
palliative transurethral resection of the prostate (TUR-P) 
and ADT at Oslo University Hospital, Aker, in the period 
1992- 2008 were identified retrospectively from medical 
records. 16 patients were excluded from the analyses due 
to lack of sufficient tissue or lack of consent. 
Clinical information was obtained from medical 
records. Retracted data included date of birth, date of 
diagnosis, date of initiation of hormonal treatment or 
orchiectomy, and date of progression. Date and cause of 
death were obtained from Statistics Norway, per May 1st 
2012.
Tissue was obtained from “The Prostate Biobank- a 
resource for urological research in Norway” (No.119 The 
Biobank Registry at Norwegian Institute of Public Health). 
One area representing normal and two areas representing 
prostate cancer tissue were marked on hematoxylin/
eosin stained sections, extracted using a 0.6 mm tissue 
core, and mounted using a semi-motorized tissue arrayer 
(TMABooster, Alphelys, Plaisir, France).
The treatment initiation date was set at the first 
time of administration of anti-androgen, luteinizing 
hormone- releasing hormone (LHRH) agonist, or date 
of orchiectomy, where applicable. Where the exact date 
of diagnosis, initiation of ADT or disease progression 
was not noted in the patient’s journal, the actuar-method 
was used to assign an event date; that is, the middle date 
between two known dates before and after diagnosis, start 
of hormonal treatment, or disease progression. 
Patients were considered to have CRPC in the case 
of two consecutive PSA rises, progression to metastatic 
disease, or when noted explicitly in the patients journal. 
Briefly, for the TMA constructed from specimens 
obtained from the “Vancouver Prostate Centre Tissue 
Bank” [36], H&E-stained slides were inspected and 
desired areas of 1 mm were extracted and mounted 
manually (Beecher Instruments, MD, USA) as duplicated 
cores. Among the 304 prostate cancer specimens, 143 
were from radical prostatectomies, 96 were from radically 
operated patients who had been pretreated with androgen 
deprivation therapy for one to twelve months prior to 
surgery, and the remaining 23 were CRPC samples 
obtained through TUR-P. The patients were operated in 
the period 1999-2009. 
Immunohistochemistry
For the Oslo ADT TMA, TMA sections of 4 μm 
were deparaffinized and antigens were retrieved at 
97°C for 20 minutes using the PT-link (Dako, Glostrup, 
Denmark) and “Target Retrieval Solution, high pH” 
(K8004, Dako) for ADRB2 whereas the slide was 
microwaved for 10 min in citrate buffer (pH 6.0) (Thermo 
Fischer Scientific, Waltham, MA) and immersed in 0.5% 
v/v hydrogen peroxide/methanol for 20 min for UGT2B15 
and UGT2B17 immunostaining. The anti-ADRB2 
antibody (MC2656, MBL International, Woburn, MA), 
the anti-UGT2B15 antibody [37], and the anti-UGT2B17 
antibody [38] were used in dilution 1:400, 1:500 and 
Oncotarget1890www.impactjournals.com/oncotarget
1:500, respectively. The immunostainings were visualized 
using the Envision Flex” (K8010, Dako) kit. Images 
were captured using a Zeiss AXI0 Imager.A1 microscope 
with an attached Zeiss AxioCamERc5s camera (Zeiss, 
Oberkochen, Germany) using Histolab 8 (Alphelys, 
Plaisir, France), and manual scoring of the staining was 
performed by pathologists AS and WW (ADRB2) or AS 
and BK (UGT2B15 and UGT2B17). For survival analyses, 
staining intensity for the spot(s) with the highest apparent 
Gleason score was chosen for further analysis. Where the 
tissue in a spot showed more than one staining intensity, 
fractions were used. In the case of two spots with the same 
apparent Gleason score from one patient, or disagreement 
regarding staining intensity, the average intensity was 
calculated and used in the analyses. The Gleason scores 
were determined by two experienced uro-pathologists (AS 
and WW). 
ADRB2 antibody specificity and sensitivity was 
tested, and is shown in Supplementary Material and 
Methods.
The immunohistochemical staining of TMAs in the 
“Vancouver Prostate Centre Tissue Bank” was performed 
as previously described [36]. Pathologist LF evaluated 
staining intensities, and the staining intensities in the 
dataset were exclusively used for correlation analyses.
For the immunohistochemical analyses of xenograft 
tumors, the paraffin-embedded tumors were in brief 
sectioned, mounted onto glass slides, and stained with 
UGT2B15 (1:500) or UGT2B17 (1:500) antibodies. 
Pathologist BK scored staining intensities.
Plasmids
Two short hairpin SureSilencingTM shRNA plasmids 
with insert sequences targeting ADRB2 mRNA, as well 
as a non-targeting shRNA as control, were purchased 
from Qiagen (Supplementary Table 1) (Qiagen, Hilden, 
Germany). Two androgen-responsive reporter constructs 
were used including the probasin and PSA promoters, 
respectively. The PSA reporter plasmid (pGL3/PSA) 
included 7 kb of the 5’- upstream region of PSA [39]. The 
probasin promoter sequence (pPB(-285/132)-LUC [40]) 
was cloned into a Gluc-ONTM Promoter clone system 
(pEZX-PG04, GeneCopoeia) expressing Luc and Secreted 
alkaline phosphatase (SEAP) as tracking gene (pEZX-
PG04-Pb-LUC). An empty pEZX-PG04 vector expressing 
SEAP was used to control for differences in transfection 
efficiency. A pCDNA3.1 vector, expressing the ADRB2 
gene (pCDNA3.1-ADRB2), was used for over-expression 
[41].
Cell lines
LNCaP cells (ATCC (VA, USA), purchased 
10/2009), were maintained in RPMI 1640 containing 
10% Fetal Bovine Serum (FBS) ((Sigma-Aldrich, 
St. Louis, MO), 100units/ml penicillin and 50mg/
ml streptomycin (InVitrogen, Carlsbad, CA) at 37oC 
with 5% CO2 and humidified air, and were given fresh 
medium every 48 hours. Stable ADRB2 knockdown 
was achieved by transfection of LNCaP cells at passage 
25 with three different shRNA sequences (two different 
ADRB2 shRNAs; shADRB2-1 and 2, and a non-targeting 
shRNA; shCtrl), using Dharmafect Duo (Dharmacon/
GE). Stably transfected cells were maintained in 200μg/
ml G418 sulphate. Cells were exclusively used between 
passage 28 and 45. Cell IDs of parental LNCaP, LNCaP 
shADRB2 and shCtrl cell lines were verified using the 
STR PowerPlex16 System (Promega, Fitchburg, WI)
(tested 07/2014). 
Stimulation of cell cultures
To study effects of androgen stimulation, LNCaP 
cells were grown in phenol red free RMPI 1640 (Life 
technologies, Carlsbad, CA) added 2% charcoal-stripped 
FBS (CSS, Gibco, Carlsbad, CA) and supplemented 
with either 1.0 or 10 nM metribolone (R1881, Roussel 
UCLAF), 1.0 or 10nM dihydrotestosterone (DHT, kindly 
provided by the Hormone Laboratory, Oslo University 
Hospital), 50 µM diclofenac sodium (DFS, Cayman 
Chemical Company, MI) or vehicle (ethanol). The cells 
were preincubated in RPMI with 2% CSS where noted.
Animal experiments
Twenty-one in-house bred, 4 week old male 
NOD-SCID gamma/null mice weighing 28.2 ± 4 g were 
administered 0.03mg/ml testosterone (Sigma-Aldrich) 
in drinking water one week prior to s.c. injection into 
the hind flank with 2 x 106 LNCaP shADRB2-2 (n 
= 10) or shCtrl (n = 11) cells suspended in Matrigel 
(1:1) (BD Biosciences, San Jose, CA). Tumor volumes 
were assessed weekly using caliper measurements and 
calculated by the formula: (length x width2)/2. Once 
tumor size reached 500mm3, the mice were surgically 
castrated under anesthesia by removal of testes and taken 
off testosterone supplementation. The mice were sacrificed 
when the tumor volumes reached 2000 mm3. The tumors 
were excised and split in two parts: One part was fresh 
frozen and used for measurement of glucuronidation 
activities, the other formalin-fixed and paraffin-embedded 
for immunohistochemical analyses. The experiment was 
approved by the National Animal Research Authority 
(FOTS ref. 7132) and was performed according to 
regulations of the Federation of European Laboratory 
Animals Science Association.
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Transient transfection and reporter assays
The LNCaP sub-cell lines were transfected using 
the Dharmafect Duo reagent. Reporter activities (secreted 
luciferase and SEAP) in medium samples were measured 
48 hours after transfection using the Secret-Pair Dual 
Luminescence Assay kit (GeneCopoeia) on a Victor 
Wallac Spectrophotometer (PerkinElmer, Waltham, 
MA). To determine intra-cellular luciferase activity cells, 
cells were lysed in 1X Reporter Lysis buffer (Promega), 
the supernatant mixed with Luciferase Assay Reagent 
(Promega) and the activity measured on a TD-20/20 
luminometer (Turner Designs, Sunnyvale, CA).
RNA extraction and real-time RT-PCR
Total RNA was extracted using the TRIzol reagent 
following manufacturers protocol (Invitrogen). 100 ng of 
total RNA was used in the qScript™ One-Step qRT-PCR 
Kit (Quanta Biosciences, Gaithersburg, MD). The RT-PCR 
reactions were performed on a CFX Connect™ Real-Time 
System (BioRad, Hercules, CA) under 48° C for 10 min; 
95°C for 5 min for the first cycle; 95°C for 15 s, 55°C for 
30 s for 40 cycles; 60 melt curve read offs from 65-95°C. 
ALAS-1 or POLR-2A mRNA expression were used for 
reference. To display relative gene expression, the ΔΔCt 
formula [42] was used. The primers used were: ADRB2 
fwd: gtcttgagggctttgtgctc, rev: ggcagctccagaagattgac; 
UGT2B15 fwd: gatcatcgaccccagagaaa, rev: 
tcactgtaaaccagccaaacc; UGT2B17 fwd: 
gatcatcgaccccagagaaa, rev: cgcccattcttaccaaatgt; 
Kallikrein 3/Prostate Specific Antigen (KLK3/PSA) fwd: 
ccctgagcacccctatcaac, rev: tgagtgtcggtgggttgtg. 
Prostate specific antigen (PSA/KLK3)
Total PSA in medium was determined by the 
AutoDELFIA ProStatus PSA Free/Total Kit (PerkinElmer 
Inc., USA) by time-resolved fluorescence on the 
AutoDELFIA instrument. Total PSA was normalized to 
the amount of protein in each sample. 
Protein extraction and immunoblot analysis
The cells were harvested, lysed in whole cell buffer 
[43], and centrifuged at 16,000 g for 20 min. Immuno-
blots were prepared and visualized as previously reported 
[37, 38]. Anti-UGT2B15 (1:1500) or anti-UGT2B17 
(1:2000) was used as primary antibodies, and anti-actin 
(1:2000, #A5060, Sigma-Aldrich) as loading control. Both 
UGT2B15 and UGT2B17 antibodies were kindly provided 
by A. Bélanger (CHU-Québec research centre) [38].
Radioligand binding and adenylyl cyclase assays
Cell membrane fractions were prepared as described 
in [44], and the ADRB2 protein binding activity was 
measured by radioligand binding assay, as previously 
described [45] with a binding buffer described in [46]. 
The total number of specific binding sites was determined. 
Ligand binding was normalized to the total amount of 
protein in the membrane fractions.
Adenylyl cyclase activity was measured by 
determining conversion of [α-32P]ATP to [32P]cAMP in 
cell membrane fractions in the presence and absence of 
10 µM isoproterenol (Sigma-Aldrich) for 20 minutes, 
and was related to whole membrane protein as previously 
described [44]. 
Formation of steroid glucuronides
LNCaP shADRB2 and shCtrl protein lysates were 
prepared by centrifugation at 890g for 10 min at 4°C 
followed by lysis by sonication on ice. The lysates were 
diluted in PBS supplied with 0.5 mM dithiothreitol (DTT) 
(GE Healthcare, Buckinghamshire, UK). Xenograft 
homogenates were prepared by homogenizing 50 µg of 
tumor tissues from mice injected with LNCaP shADRB2 
and shCtrl in 250 µL of ice-cold PBS supplied with 0.5 
mM DTT using a Homogenizer Motor Drives (Glass-Col 
Homogenizer #099C-K54, Terre-Haute, IN, USA). Steroid 
glucuronidation assays were performed by adding 10 µL 
of lysates (8.8 µg/µL) or xenograft homogenates (5 µg/
µL) to a glucuronidation assay buffer (50 mM Tris-HCl 
pH 7.5, 10 mM MgCl2, 10μg/mL phosphatidylcholine, 
1 mM uridine 5’-diphosphoglucuronic acid (UDPGA), 
2.5 μg/mL pepstatin, 0.5 μg/mL leupeptin, 0.025 μg/mL 
alamethicin, and 100 μM of either testosterone, DHT, 
3α-Diol, or androsterone dissolved in ethanol). The 
mixtures were incubated at 37°C for 1 or 4 hours (cell 
lysates or xenograft homogenates, respectively) before 
quenching the glucuronidation reactions with 2 nM ice-
cold methanol:butylated hydroxytoluene (BHT). Proteins 
were centrifuged at 13,000 rpm for 10 minutes at 4°C to 
pellet the protein precipitate. Supernatants were used for 
glucuronide quantification by LC-MS/MS as previously 
reported [47]. Cell lysate samples used for glucuronidation 
assays were prepared with the same dilutions of those used 
for immunoblotting assays, so the protein levels directly 
correspond to the glucuronidation activity. HEK293-cells 
and ethanol were used as negative controls, and a pool of 
human liver samples as positive control. 
Androgen quantification
Testosterone levels in cell cultures was measured 
by a multi-steroid LC-MS/MS assay as described by [48] 
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with the following modifications: Isotope-labeled internal 
standards (10 µl) and 190 µl 50 % acetonitrile was added 
to 85 µl of each calibrator and quality control as well as to 
each cell pellet lysate. The samples were sonicated (40% 
amplitude, 10 pulses of 1s), equilibrated at RT for one 
hour, and extracted by liquid-liquid extraction with 850 
µl ethylacetate:hexane (80:20). After centrifugation, 650 
µl of the organic phase was dried under a stream of N2 
for 30 minutes at 40°C. The samples were reconstituted 
in 50 µl 25% methanol, and 10 µl of each sample was 
injected into a Waters Xevo TQ-S that was coupled to 
an i-class Acquity UPLC. The chromatographic system 
consisted of a 100 x 2.1 mm Acquity BEH C-18 column 
(1.8 µM particle size) heated to 60° C, and two mobile 
phases consisting of Milli-Q purified water with 0.05% 
ammonium hydroxide (A) and methanol with 0.05% 
ammonium hydroxide (B). Samples were separated by 
a linear gradient from 30% to 75% mobile phase B over 
7.5 min at a flow-rate of 0.4 ml/min. Testosterone was 
quantitated by electrospray ionisation in positive mode, 
and multiple reaction monitoring as described previously 
[48]. Concentrations were calculated as fmol per cell 
pellet or tumor tissue weight.
Statistics
Time to development of CRPC and time to prostate 
cancer-specific mortality was analyzed by competing risk 
regression using the Fine and Grey model [49], while Cox 
proportional hazards modelling was applied for all-cause 
mortality analysis. The proportional hazards assumption 
was assessed by a test based on Schoenfeld residuals. 
There was no evidence of violation of the assumption 
in any model (all p-values > 0.13). Correlations were 
calculated using Spearman’s rank correlation, due to non-
normality of the data. For all other statistical analyses, a 
two-tailed Student’s t-test or Fischer exact test were used 
to determine statistical significance. For xenograft tumor 
glucuronide formation, values were log10-transformed 
to invoke normally distributed data prior to parametric 
testing. Statistics were performed using SPSS version 
18, STATA version 12 and Microsoft Excel. A two-sided 
p-value of < 0.05 was considered statistically significant 
for all analyses.
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